Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

February 20, 2021

Study Completion Date

March 13, 2021

Conditions
Schizophrenia
Interventions
DRUG

Evenamide

oral capsules for 4 weeks of treatment

DRUG

Placebo

oral capsules for 4 weeks of treatment

Trial Locations (14)

20877

CBH Health, LLC, Gaithersburg

78754

Community Clinical Research CCR, Austin

91206

Behavioral Research Specialists, LLC, Glendale

160012

Post Graduate Institute of Medical Education and Research, Chandigarh

500034

Asha Hospital, Hyderabad

520002

Help Hospitals Clinical Research Department, Vijayawada

600116

Sri Ramachandra Medical College, Department of Psychiatry, Chennai

Unknown

St. John's Medical College Hospital, Koramangala

Mangala Hospital and Mangala Kidney Foundation, Department of Psychiatry, Mangalore

IQRAA Psychiatry Care and Rehabilitation Centre, Kozhikode

Deenanath Mangeshkar Hospital Research Center, Pune

Sujata Birla Hospital, Pune

Dayanand Medical College & Hospital, Ludhiana

Ahana Hospital LLP, Madurai

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT04461119 - Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia | Biotech Hunter | Biotech Hunter